SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-038547
Filing Date
2023-10-27
Accepted
2023-10-27 17:00:22
Documents
13
Period of Report
2023-10-23
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 48005
  Complete submission text file 0001493152-23-038547.txt   267712

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE cldi-20231023.xsd EX-101.SCH 3813
3 XBRL DEFINITION FILE cldi-20231023_def.xml EX-101.DEF 26683
4 XBRL LABEL FILE cldi-20231023_lab.xml EX-101.LAB 36833
5 XBRL PRESENTATION FILE cldi-20231023_pre.xml EX-101.PRE 25307
7 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5606
Mailing Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 858-794-9600
Calidi Biotherapeutics, Inc. (Filer) CIK: 0001855485 (see all company filings)

IRS No.: 862967193 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40789 | Film No.: 231356219
SIC: 2836 Biological Products, (No Diagnostic Substances)